Enveric Biosciences, Inc. (ENVB)
$
0.61
-0.01 (-1.64%)
Key metrics
Financial statements
Free cash flow per share
-2.5120
Market cap
1.8 Million
Price to sales ratio
5.1789
Debt to equity
0
Current ratio
2.4253
Income quality
0.6558
Average inventory
0
ROE
-3.4149
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Enveric Biosciences, Inc., a pharmaceutical company headquartered in Naples, Florida, focuses on developing innovative cannabinoid medicines specifically for cancer care. The total costs and expenses for the company are -$9,632,266.00 reflecting its overall spending. The net income ratio is 0.00 indicating the company's profitability margin and ability to generate profits from its operations. Additionally, the operating income ratio stands at 0.00 which serves to indicate the company's operational profitability margin. The income before tax ratio is 0.00 reflecting the pre-tax margin and the company's efficiency in managing its revenue before it is taxed. Despite these metrics, the company reported a net loss of -$9,574,987.00 indicating challenges in its operations and the need for further strategic adjustments to improve its financial performance. The products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for addressing cancer-related distress; EVM-301 targeting mental health conditions; EV102, a topical cannabinoid cream; and EV101, a combination therapy involving cannabinoids and chemotherapy. In the financial landscape, Enveric Biosciences' stock is accessible at $0.60 making it suitable for budget-conscious investors looking for affordable investment opportunities. The stock has an average trading volume of 507,803.00 indicating moderate liquidity, which can appeal to investors seeking efficient entry and exit points. With a market capitalization of $1,519,329.00 the company is classified as a small-cap player within the financial markets. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its focused research and development initiatives. Furthermore, it belongs to the Healthcare sector, which drives innovation and growth, making it a noteworthy entity for anyone interested in the advancements in cannabinoid therapies for healthcare.
Is Enveric Biosciences, Inc. (ENVB) a good investment?
Investing in Enveric Biosciences, Inc. (ENVB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Enveric Biosciences, Inc. (ENVB)'s stock forecast?
Analysts predict Enveric Biosciences, Inc. stock to fluctuate between $0.56 (low) and $8.25 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Enveric Biosciences, Inc.'s market capitalization?
As of 2025-10-28, Enveric Biosciences, Inc.'s market cap is $1,519,329, based on 2,471,660 outstanding shares.
How does Enveric Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Enveric Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Enveric Biosciences, Inc. pay dividends?
Enveric Biosciences, Inc. pays dividends. The current dividend yield is 0.33%, with a payout of $0.02 per share.
How can I buy Enveric Biosciences, Inc. (ENVB) stock?
To buy Enveric Biosciences, Inc. (ENVB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENVB. Place an order (Market, Limit, etc.).
What is the best time to invest in Enveric Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Enveric Biosciences, Inc. stock ever split?
Enveric Biosciences, Inc.'s last stock split was 1:12 on 2025-10-28.
How did Enveric Biosciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$19.04 | Growth: 135.35%.
Where can I find Enveric Biosciences, Inc.'s investor relations reports?
Visit https://www.enveric.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Enveric Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Enveric Biosciences, Inc. stock?
All-time high: $2,805 (2021-09-10) | All-time low: $0.56 (2025-09-19).
What are the key trends affecting Enveric Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental heal.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 share.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) to its request for a Pre-Investigational New Drug (pre-IND) Type B meeting for its lead program, EB-003. In its response, the FDA indicated that the questions f.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, post-traumatic stress disorder (PTSD), and other neuropsychiatric disorders, today announced the successful completion of 7-day Dose Range Finding (DRF) toxicology studies in two preclinical species for its lead drug candidate, EB-003. The results define the Maxi.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an update on the Company's development program and recent events. The full text of the letter follows. A MESSAGE FROM.
See all news
